Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031259 | 0.84 | ALDH1A1 (0.56) | SOS1MAPTCYP19A1STAT3RAB9A | |
| SCHEMBL11049170 | 0.84 | MAPT (0.69) | SOS1MAPTCYP19A1RAB9AKMT2A | |
| SCHEMBL9978289 | 0.84 | MAPT (0.69) | SOS1MAPTCYP19A1RAB9AKMT2A | |
| SCHEMBL14935499 | 0.84 | MAPT (0.69) | SOS1MAPTCYP19A1RAB9AKMT2A | |
| SCHEMBL11296000 | 0.82 | MAPT (0.67) | SOS1MAPTCYP19A1RAB9AKMT2A | |
| SCHEMBL11299049 | 0.82 | MAPT (0.67) | SOS1MAPTCYP19A1RAB9AKMT2A | |
| SCHEMBL28180874 | 0.81 | MAPT (0.54) | SOS1MAPTCYP19A1RAB9AKMT2A | |
| SCHEMBL1509290 | 0.80 | HSD17B10 (0.54) | MAPTRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL29523356 | 0.80 | GSK3B (0.44) | MAPTALDH1A1SMN1; SMN2KDM4ERELA | |
| SCHEMBL2126765 | 0.80 | SNCA (0.50) | MAPTCYP19A1RAB9ANPC1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144135-B1 | METHOD OF MAKING NON-LINEAR OPTICAL POLYMER | BATTELLE MEMORIAL INSTITUTE (US) | 2004-06-16 | — | — | EP | claimed |
| US-5677107-A | PHOTOHARDENABLE FILM WITH PHOTORESPONSIVE AGENT; IRRADIATING SELECTIVE PORTIONS OF CROSS-SECTIONAL PATTERNS THAT ARE TO BE COLORED DIFFERENTLY | SPECTRA GROUP LIMITED, INC. (US) | 1997-10-14 | — | — | US | claimed |
| EP-0445202-A1 | MATERIALS EXHIBITING LARGE NON LINEAR OPTICAL PROPERTIES. | INTELLPROP CORP (PA) | 1991-09-11 | — | — | EP | claimed |
| US-4958895-A | Optical waveguides | GEC-MARCONI LIMITED (GB) | 1990-09-25 | — | — | US | claimed |
| WO-1990006535-A1 | MATERIALS EXHIBITING LARGE NON LINEAR OPTICAL PROPERTIES | INTELLPROP CORPORATION (PA) | 1990-06-14 | — | — | WO | claimed |
| EP-0348220-A2 | Optical waveguides | GEC-MARCONI LIMITED (GB) | 1989-12-27 | — | — | EP | claimed |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | THE JACKSON LABORATORY (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2276394-B1 | VISION CORRECTING DEVICE TO TREAT AND PREVENT LOSS OF VISUAL ACUITY | CRT TECHNOLOGY INC (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | disclosed |
| US-7905595-B2 | System and method to treat and prevent loss of visual acuity | CRT TECHNOLOGY, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-0455020-A2 | Optical modulator | Alcatel SEL Aktiengesellschaft (DE) | 1991-11-06 | — | — | EP | disclosed |
| US-5011623-A | Nonlinear optical material and nonlinear optical device | CANON KABUSHIKI KAISHA (JP) | 1991-04-30 | — | — | US | disclosed |
| EP-0406888-A2 | Nonlinear optical polymer composition and method for producing the same | SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) | 1991-01-09 | — | — | EP | disclosed |
| US-4958895-A | Optical waveguides | GEC-MARCONI LIMITED (GB) | 1990-09-25 | — | — | US | disclosed |
| EP-0351832-A2 | Nonlinear optical material and nonlinear optical device | CANON KABUSHIKI KAISHA (JP) | 1990-01-24 | — | — | EP | disclosed |
| EP-0348220-A2 | Optical waveguides | GEC-MARCONI LIMITED (GB) | 1989-12-27 | — | — | EP | disclosed |
| EP-0338702-A1 | Nonlinear optical materials | NIPPON OIL CO. LTD. (JP) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | BAK1, SSB, MRE11 | SOS1 1936/4885MAPT 3931/4885CYP19A1 3919/4885 |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | BAK1, SSB, MRE11 | SOS1 1936/4885MAPT 3931/4885CYP19A1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.